NSAID, she said.

It’s hard to make sense of the data coming out purporting cancer cures as another indication for non-steroidal anti-inflammatory drug (NSAID) use. The latest is a retrospective case control study nested in the Nurses’ Health Study. Outcomes following diagnoses of ovarian cancer (n=1143)—measured by linking to SEER data—were compared based on whether the patient had recent, regular exposure to an NSAID. Recent meaning within two years and regular meaning at least twice weekly. Post-diagnosis NSAID users (n=568) had one-third less risk of ovarian cancer-specific mortality (HR 0.67-0.68). What’s more, women who began using NSAIDs only after diagnosis (n=125) had less than half the risk of ovarian cancer-specific mortality (HR 0.44-0.46). TBL: There may be something to NSAID use as a component of secondary prevention for ovarian cancer, but it remains a soft call until prospective data emerges. | Merritt, Lancet Oncol 2018